Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2203359/biogen-inc-biib-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2203359
Dec 28, 2023 - The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.
0
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
0
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
https://www.zacks.com/stock/news/2199443/biogen-s-biib-rare-disease-drug-skyclarys-gets-chmp-nod-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199443
Dec 18, 2023 - Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.
0
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
0